lunes, 21 de marzo de 2016

Prostate Cancer Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Prostate Cancer Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Prostate Cancer Treatment–Health Professional Version (PDQ®)







SECTIONS





Changes to This Summary (03/17/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Updated Wilt et al. as reference 14.
Added text to provide evidence about continuous versus intermittent hormonal therapy, which included a systematic review of 15 randomized trials that compared continuous versus intermittent androgen deprivation therapy (ADT) for patients with advanced or recurrent prostate cancer and found no significant difference in overall survival (OS), prostate cancer-specific survival, and progression-free survival (PFS); the meta-analysis fulfilled prespecified criteria for noninferiority of OS (cited Magnan et al. as reference 38 and level of evidence 1iiA). Also added that there was little difference in patient-reported quality of life (QOL).
Added text to state that the addition of chemotherapy has been shown in randomized trials to improve OS compared with hormonal therapy alone.
Added text to state that in one trial, 790 patients with metastatic, hormone-sensitive disease were randomly assigned to receive ADT with or without docetaxel and provided median follow-up data (cited Sweeney et al. as reference 3 and level of evidence 1iiA).
Added text to provide evidence about continuous versus intermittent hormonal therapy, which included a systematic review of 15 randomized trials that compared continuous versus intermittent ADT for patients with advanced or recurrent prostate cancer and found no significant difference in OS, prostate cancer-specific survival, and PFS; the meta-analysis fulfilled prespecified criteria for noninferiority of OS (cited Magnan et al. as reference 38 and level of evidence 1iiA). Also added that there was little difference in patient-reported QOL.
Added text to provide evidence about continuous versus intermittent hormonal therapy, which included a systematic review of 15 randomized trials that compared continuous versus intermittent ADT for patients with advanced or recurrent prostate cancer and found no significant difference in OS, prostate cancer-specific survival, and PFS; the meta-analysis fulfilled prespecified criteria for noninferiority of OS (cited Magnan et al. as reference 17 and level of evidence 1iiA). Also added that there was little difference in patient-reported QOL.
Added this new section.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: March 17, 2016

No hay comentarios:

Publicar un comentario